DRMA · Dermata Therapeutics Inc
United States · RS rating 13 · As of 2026-11-03
| Price | 0.85 USD |
|---|---|
| 1-day change | +12.6% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 18 / 23 / 11 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 4 / 32 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -54.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +75.2% |
| Market cap (USD) | $5.1M |